Session Details

As part of the ISCT 2024 Elevator Pitch Competition, 15+ poster presenters are invited to give a 2-minute pitch of their research. Presenters will concisely and effectively identify the goal of their research, the outcomes and impact of their work, and their unique selling proposition, thus demonstrating to delegates the importance of their research to the field.

All presentations are evaluated by the Cytotherapy editorial leadership team and the highest-scoring presenter will win the Cytotherapy-sponsored "Best Elevator Pitch Abstract Award" ($1,000 USD).

1. Diepiriye Iworima, PhD, The University of British Columbia, Canada, "Identifying Critical Process Parameters And Critical Quality Attributes Associated With Scalable Manufacture Of Stem Cell-Derived Pancreatic Endocrine Cell Types"
2. Andrew Bruce, BS, ProKidney, United States, "Adaptive Epithelial Cells in rilparencel Express Renal Reparative Markers"
3. Kanupriya Daga, PhD, University of Georgia College of Engineering, University of Georgia, United States, "Mesenchymal Stromal Cell-Derived Extracellular Vesicles Modulate Microglia Morphology And Mitochondrial Content"
4. Jonathan Al-Saadi, MD, Karolinska Institutet; Karolinska Universitetssjukhuset; MedTechLabs, Sweden, "Direct parenchymal delivery to any organ or tumor via next generation endovascular technique – minimally invasive and efficient method for targeted cell and gene therapy"
5. Madhavi Lakkaraja, MD, MPH, Fred Hutchinson Cancer Center; University of Washington School of Medicine, United States, "Rabbit Antithymocyte Globulin Exposure Affects Outcomes: Ancillary Analysis from BMT CTN 1202"
6. Devin Mcavoy, BS, Memorial Sloan Kettering Cancer Center, United States, "Navigating Lymphocyte Reconstitution: Insights into aGVHD Phases"
7. Paul Beavis, PhD, Peter MacCallum Cancer Centre, Australia, "CRISPR engineering of armored CAR T cells enables tumor-restricted payload delivery with enhanced safety and efficacy"
8. Monica Klein, MD, Mayo Clinic Minnesota, United States, "Increased Frequency Of Chromosomal Abnormalities In Multiple System Atrophy Mesenchymal Stromal Cells"
9. Shirley Mei, PhD, MSc, Northern Therapeutics Inc; The Ottawa Hospital Research Institute, Canada, "The AMETHYST (Advanced Mesenchymal Enhanced cell THerapY for SepTic) Trial: A First-In-Human, Dose-Escalation Phase 1 Safety Trial of Genetically Enhanced MSCs (GEM00220) Appeared Safe and Well Tolerated in Patients with Septic Shock"
10. Ankita Jain, PhD, University of Pennsylvania Perelman School of Medicine, United States, "Harnessing Potent Naïve Like T Cells for Precision CAR T Manufacturing"
11. Sana Kaisar, BSC, MSc, Imperial College London; The Jackson Laboratory, United Kingdom, "Development of a quantification method for immune-checkpoint inhibitor-induced myocarditis."
12. Paul Dyer, PhD, Halo Labs Ltd, United Kingdom, "Determination of contaminating particles in cell therapy products; a proof of principle study."
13. Maik Luu, PhD, University Hospital Würzburg, Germany, "T2EVOLVE: Standardization of pre-clinical and clinical development of engineered T cell therapy in Europe; a cross functional multi stakeholder initiative"
14. Hamid Ebrahimi Orimi, PhD, McGill University, Canada, "Biofabrication of Perfusable Stem Cell-Derived Pancreatic Tissues Using Sacrificial Embedded Writing Approach"
15. Michael Lanero Fidalgo, MSc, MBA, Treefrog Therapeutics, France, "Off-the-shelf Bioreactor Produced, iPSC-derived Neural Microtissues Containing Dopaminergic Neurons Innervate The Striatum And Normalize Behavior In A Parkinson Rat Model"